AbbVie Reports Phase 2 Data for Lasmiditan in Crohn's disease

AbbVie today announced Phase 2 results for Lasmiditan in patients with Crohn's disease. The study demonstrated that Lasmiditan demonstrates sustained long-term efficacy compared to standard of care or placebo. These results provide important insights into the treatment of Crohn's disease and support the continued development of Lasmiditan in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Lasmiditan was consistent with previous observations, with no new safety signals identified.